pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
785
stories
Sep 11, 26
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
fiercebiotech
Sep 11, 26
GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck
fiercebiotech
Sep 11, 26
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
biospace
Sep 10, 26
Takeda’s long-term R&D head announces exit after major pipeline reorganization
biospace
Sep 10, 26
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
Sep 10, 26
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
fiercebiotech
Sep 9, 26
CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
fiercebiotech
Sep 9, 26
Solstice rises with $225M to develop next-gen CTLA-4 drug from China
biospace
Sep 9, 26
Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic
endpoints
Sep 9, 26
A new immuno-oncology play raises $225M for a next-generation drug
biopharma dive
Sep 9, 26
Beyond China: Five other overseas destinations for biopharma dollars
biospace
Sep 9, 26
Steady stream of crossover rounds stock biotech's IPO pipeline
biospace
Sep 9, 26
Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
fiercebiotech
Sep 8, 26
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
biospace
Sep 8, 26
BrainChild Bio targets deadly pediatric brain cancer with $116M series A
biospace
Sep 8, 26
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
fiercebiotech
Sep 8, 26
Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
fiercebiotech
Sep 8, 26
Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint
fiercebiotech
Sep 8, 26
4 CDMOs to consider when outsourcing manufacturing
biospace
Sep 8, 26
Reeling from past failures, Parkinson's pipeline enters 'era of diversification'
biospace
Sep 8, 26
Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
fiercebiotech
Sep 8, 26
Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability
fiercebiotech
Sep 7, 26
Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped
fiercebiotech
Sep 4, 26
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
biopharma dive
Sep 4, 26
US-China biotech NeuShen gets $80M to develop brain-health drugs
endpoints
Sep 4, 26
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
biopharma dive
Sep 4, 26
Pfizer punts Seagen ADC, further muddying value of the $43B buyout
biospace
Sep 3, 26
GSK wagers up to $1.3B on a different kind of cancer drug
biopharma dive
Sep 3, 26
Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readout
fiercebiotech
Sep 3, 26
Pfizer shares ADC rights with Medicus; RevMed updates lung cancer data
endpoints
← prev
page 13 of 27
next →